Platelet Transfusion in Critical Care and Surgery: Evidence-Based Review of Contemporary Practice and Future Directions

Shock

Volumn 47, Issue 5, 2017, Pages 537-549

  Etchill, Eric W ^a   Myers, Sara P ^a   Raval, Jay S ^b   Hassoune, Adnan ^c   Sengupta, Anirban ^d   Neal, Matthew D ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Blood platelets; platelet transfusion; sepsis; surgical intensive care; synthetic platelets; wounds and injuries

Indexed keywords

ANTICOAGULANT THERAPY; BLOOD BANK; CLINICAL PRACTICE; CRITICALLY ILL PATIENT; CRYOPRESERVATION; END STAGE LIVER DISEASE; EVIDENCE BASED PRACTICE; FREEZE DRYING; HEART SURGERY; HUMAN; INJURY; INTENSIVE CARE; LIVER GRAFT; NEUROSURGERY; OBSTETRICS; PATHOGENESIS; POINT OF CARE TESTING; PRACTICE GUIDELINE; PROPHYLAXIS; QUALITY CONTROL; REVIEW; SEPSIS; SURGERY; SURGICAL PATIENT; SYSTEMATIC REVIEW; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; TREATMENT CONTRAINDICATION; PROCEDURES; STANDARDS; THROMBOCYTOPENIA;

CRITICAL CARE; HUMANS; PLATELET TRANSFUSION; THROMBOCYTOPENIA;

EID: 84995476569     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000794     Document Type: Review

References (158)

1. Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM: The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest 139(2):271-278, 2011.
2. Stanworth SJ, Walsh TS, Prescott RJ, Lee RJ, Watson DM, Wyncoll DL: Intensive care study of coagulopathy investigators. Thrombocytopenia and platelet transfusion in UK critical care: a multicenter observational study. Transfusion (Paris) 53(5):1050-1058, 2013.
3. McIntyre L, Tinmouth AT, Fergusson DA: Blood component transfusion in critically ill patients. Curr Opin Crit Care 19(4):326-333, 2013.
4. Arnold DM, Crowther MA, Cook RJ, Sigouin C, Heddle NM, Molnar L, Cook DJ: Utilization of platelet transfusions in the intensive care unit: indications, transfusion triggers, and platelet count responses. Transfusion (Paris) 46(8): 1286-1291, 2006.
5. Bjursten H, Al-Rashidi F, Dardashti A, Bronden B, Algotsson L, Ederoth P: Risks associated with the transfusion of various blood products in aortic valve replacement. Ann Thorac Surg 96(2):494-499, 2013.
6. Vanderschueren S, De Weerdt A, Malbrain M, Vankersschaever D, Frans E, Wilmer A, Bobbaers H: Thrombocytopenia and prognosis in intensive care. Crit Care Med 28(6):1871-1876, 2000.
7. Strauss R, Wehler M, Mehler K, Kreutzer D, Koebnick C, Hahn EG: Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 30(8):1765-1771, 2002.
8. British Committee for Standards in Haematology, B.T.T.F. Guidelines for the use of platelet transfusions. Br J Haematol 122(1):10-23, 2003.
9. Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD, Cohn CS, Fung MK, Grossman BJ, et al.: Wong ECm Tobian AA, AABB. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 162(3):205-213, 2015.
10. Slichter SJ: Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program; 172-178, 2007.
11. Wandt H, Schafer-Eckart K, Greinacher A: Platelet transfusion in hematology, oncology and surgery. Dtsch Arztebl Int 111(48):809-815, 2014.
12. Lin Y, Foltz LM: Proposed guidelines for platelet transfusion. BCMJ 47(5):245-248, 2005.
13. Chan KH, Mann KS, Chan TK: The significance of thrombocytopenia in the development of postoperative intracranial hematoma. J Neurosurg 71(1): 38-41, 1989.
14. Pidcoke HF, Spinella PC, Ramasubramanian AK, Strandenes G, Hervig T, Ness PM, Cap AP: Refrigerated platelets for the treatment of acute bleeding: a review of the literature and reexamination of current standards. Shock 41(suppl 1):51-53, 2014.
15. Aiboshi J, Moore EE, Ciesla DJ, Silliman CC: Blood transfusion and the two-insult model of post-injury multiple organ failure. Shock 15(4):302-306, 2001.
16. Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekley AC, Sebesta J, Jenkins D, Wade CE, Holcomb JB: The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 63(4):805-813, 2007.
17. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzaval LA, Schreiber MA, Gonzalez EA, Pomper GJ, Perkins JG, Spinella PC, et al.: Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 248(3):447-458, 2008.
18. Holcomb JB, Zarzabal LA, Michalek JE, Kozar RA, Spinella PC, Perkins JG, Matijevic N, Dong JF, Pati S, Wade CE, et al.: Increased platelet: RBC ratios are associated with improved survival after massive transfusion. J Trauma 71(2 suppl 3):S318-S328, 2011.
19. Cap AP, Spinella PC, Borgman MA, Blackvourne LH, Perkins JG: Timing and location of blood product transfusion and outcomes in massively transfused combat casualties. J Trauma Acute Care Surg 73(2 suppl 1):S89-S94, 2012.
20. Holcomb JB, del Junco DJ, Fox EE, Wade CE, Cohen MJ, Schreiber MA, Alarcon LH, Bai Y, Brasel KJ, Bulger EM, et al.: The prospective, observational, multi-center, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg 148(2):127-136, 2013.
21. del Junco DJ, Holcomb JB, Fox EE, Brasel KJ, Phelan HA, Bulger EM, Schreiber MA, Muskat P, Alarcon LH, Cohen MJ, et al.: PROMMTT Study Group. Resuscitate early with plasma and platelets or balance blood products gradually: findings from the PROMMTT study. J Trauma Acute Care Surg 75(1 Suppl 1):S24-S30, 2013.
22. Simms ER, Hennings DL, Hauch A, Wascom J, Fontenot TE, Hunt JP, McSwain NE Jr, Meade PC, Myers L, Duchesne JC: Impact of infusion rates of fresh frozen plasma and platelets during the first 180 minutes of resuscitation. J Am Coll Surg 219(2):181-188, 2014.
23. Murdock AD, Berseus O, Hervig T, Strandenes G, Lunde TH: Whole blood: the future of traumatic hemorrhagic shock resuscitation. Shock 41(1):62-69, 2014.
24. Rahbar E, Cardenas JC, Matljevic N, Del Junco D, Podbiekski J, Cohen MJ, Cotton BA, Holcomb JB, Wade CE, Early Whole Blood Investigators. Trauma, time and transfusions: a longitudinal analysis of coagulation markers in severely injured trauma patients receiving modified whole blood or component blood products. Shock 44(5):417-425, 2015.
25. Nardi G, Agostini V, Rondinelli B, Russo E, Bastianini B, Bini G, Bulgarelli S, Cingolani E, Donato A, Gambale G, et al.: Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. Crit Care Lond Engl 19:83, 2015.
26. Stephens CT, Gumbert S, Holcomb JB: Trauma-associated bleeding: manage-ment of massive transfusion. Curr Opin Anaesthesiol 29:250-255, 2016.
27. Camazine MN, Hemmila MR, Leonard JC, Jacobs RA, Horst JA, Kozar RA, Bochicchio GV, Nathens AB, Cryer HM, Spinella PC: Massive transfusion policies at trauma centers participating in the American College of Surgeons Trauma Quality Improvement Program. J Trauma Acute Care Surg 78(6 suppl 1):S48-S53, 2015.
28. Hallet J, Lauzier F, Maillouc O, Trottier V, Archambault P, Zarychanski R, Turgeon AF: The use of higher platelet: RBC transfusion ratio in the acute phase of trauma resuscitation: a systematic review. Crit Care Med 41(12): 2800-2811, 2013.
29. Sambasivan CN, Kunio NR, Nair PV, Zink KA, Michalek JE, Holcomb JB, Schreiber MA, Wade CE, Brasel KJ, Vercruysse G, et al.: High ratios of plasma and platelets to packed red blood cells do not affect mortality in nonmassively transfused patients. J Trauma 71(2 Suppl 3):S329-S336, 2011.
30. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, del Junco DJ, Brasel KJ, Bulger EM, Callcut RA, et al.: Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 313(5):471-482, 2015.
31. McDaniel LM, Etchill EW, Raval JS, Neal MD: State of the art: massive transfusion. Transfus Med 24(3):138-144, 2014.
32. Murphy CH, Hess JR: Massive transfusion: red blood cell to plasma and platelet unit ratios for resuscitation of massive hemorrhage. Curr Opin Hematol 22(6):533-539, 2015.
33. Green L, Knight M, Seeney F, Hopkinson C, Collins PW, Collis RE, Simpson NA, Weeks A, Stanworth SJ: The haematological features and transfusion management of women who required massive transfusion for major obstetric haemorrhage in the UK: a population based study. Br J Haematol 172(4):616-624, 2016.
34. Butwick AJ, Goodnough LT: Transfusion and coagulation management in major obstetric hemorrhage. Curr Opin Anaesthesiol 28(3):275-284, 2015.
35. Beutler E: Platelet transfusions: the 20, 000/microL trigger. Blood 81(6):1411-1413, 1993.
36. Gaydos LA, Freireich EJ, Mantel N: The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. NEngl J Med 266:905-909, 1962.
37. Slichter SJ, Harker LA: Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 7(3):523-539, 1978.
38. Stanworth SJ, Hyde C, Heddle N, Rebulla P, Brunskill S, Murphy MF: Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2004:CD004269, 2004.
39. Estcourt LJ, Stanworth SJ, Doree C, Hopewell S, Trivella M, Murphy MF: Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev; 2015;CD010983, 2015.
40. Segal HC, Briggs C, Kuka S, Casbard A, Harrison P, Machin SJ, Murphy MF: Accuracy of platelet counting haematology analysers in severe thrombocytopenia and potential impact on platelet transfusion. Br J Haematol 128(4):520-525, 2005.
41. Hunt BJ: Bleeding and coagulopathies in critical care. N Engl J Med 370(22):847-859, 2014.
42. Lieberman L, Bercovitz RS, Sholapur NS, Heddle NM, Stanworth SJ, Arnold DM: Platelet transfusions for critically ill patients with thrombocytopenia. Blood 123(8):1146-1151, 2014.
43. Brecher ME: The platelet prophylactic transfusion trigger: when expectations meet reality. Transfusion (Paris) 47(2):188-191, 2007.
44. Kang Y, Audu P: Coagulation and liver transplantation. Int Anesthesiol Clin 44(4):17-36, 2006.
45. Vincent JL, Sakr Y, Sprung CL, Ranierl VM, Reinhart K, Gerlach H, Lorena R, Carlet J, Le Gall JR, Payen D: Sepsis occurrence in acutely ill patients investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34(2):344-353, 2006.
46. Martin GS: Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther 10(6):701-706, 2012.
47. Zimmerman JL: Use of blood products in sepsis: an evidence-based review. Crit Care Med 32(11 suppl):S542-S547, 2004.
48. Murthy T: Blood transfusion practices in sepsis. Indian J Anaesth 58(5):643-646, 2014.
49. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36(1):296-327, 2008.
50. Dellinger RP, Levy MM, Rhodes FA, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Crit Care Med 41(2):580-637, 2013.
51. Kaufman RM, Djubegovic S, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD, Cohn CS, Fung MK, Grossman BJ, et al.: Tobian AA; AABB. Platelet transfusion: a clinical practice guideline from the AABB. An Intern Med 162(3):205-213, 2015.
52. Tagariello G, Castaman G, Falanga A, Santoro R, Napolitano M, Storti S, Venery D, Basso M, Candiotto L, Tassinari C, et al.: GMEMA Haemostasis and Thrombosis working party. Italian daily platelet transfusion practice for haematological patients undergoing high dose chemotherapy with or without stem cell transplantation: a survey by the GIMEMA Haemostasis and Thrombosis Working Party. Blood Transfus 14:521-526, 2016.
53. Fitchett D, Elkelboom J, Fremes S, Mazer D, Singh S, Bittira B, Brister S, Graham J, Gupta M, Karkouti K, et al.: Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. Can J Cardiol 25(12):683-689, 2009.
54. Douketis JD, Spyropoulos AC, Apencer FA, Mayr M, Jaffer AK, Eckman MH, Dunn AS, Kunz R, American College of Chest Physicians. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Preven-tion of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 suppl):e326S-e350S, 2012.
55. Shore-Lesserson L, Manspeizer HE, DePerlo M, Francis S, Vela-Cantos F, Ergin MA: Thromboelastography-guided transfusion algorithm reduces trans-fusions in complex cardiac surgery. Anesth Analg 88(2):312-319, 1999.
56. Toth O, Calatzis A, Penz S, Losonczy H, Siess W: Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96(6):781-788, 2006.
57. Kashuk JL, Moore EE, Wohlauer M, Johnson JL, Pezold M, Lawrence J, Biffl WL, Burlew CC, Barnett C, Sawyer M, et al.: Initial experiences with point-of-care rapid thrombelastography for management of life-threatening postinjury coagulopathy. Transfusion (Paris) 52(1):23-33, 2012.
58. Cotton BA, Faz G, Hatch QM, Radwan ZA, Podbielski J, Wade C, Kozat RA, Holcomb JB: Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission. J Trauma 71(2):407-414, 2011.
59. Kutcher ME, Redick BJ, McCreery RC, Crane IM, Greenberg MD, Cachola LM, Nelson MF, Cohen MJ: Characterization of platelet dysfunction after trauma. J Trauma Acute Care Surg 73(1):13-19, 2012.
60. Windelov NA, Sorensen AM, Perner A, Wanscher M, Larsen CF, Ostrowki SR, Johansson PI, Rasmussen LS: Platelet aggregation following trauma: a prospective study. Blood Coagul Fibrinolysis 25(1):67-73, 2014.
61. Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N, Misso K, Ross J, Severens J, Klejinen J: Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effec-tiveness analysis. Health Technol Assess Winch Engl 19(58):1-228, 2015.
62. Cap A, Hunt BJ: The pathogenesis of traumatic coagulopathy. Anaesthesia 70(suppl 1):96-101, 2015.
63. Leemann H, Lustenberger T, Talving P, Kobayashi L, Bukur M, Brenni M, Bruesch M, Spahn DR, Keel MJ: The role of rotation thromboelastometry in early prediction of massive transfusion. J Trauma 69(6):1403-1408, 2010.
64. Tauber H, Innerhofer P, Breitkopf R, Westermann I, Beer R, El Attal R, Strasak A, Mittermayer M: Prevalence and impact of abnormal ROTEM1 assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'. Br J Anaesth 107(3):378-387, 2011.
65. Johansson PI, Sorenson AM, Larsen CF, Windelov NA, Stensballe J, Perner A, Rasmussen LS, Ostrowski SR: Low hemorrhage-related mortality in trauma patients in a Level I trauma center employing transfusion packages and early thromboelastography-directed hemostatic resuscitation with plasma and platelets. Transfusion (Paris) 53(12):3088-3099, 2013.
66. Harr JN, Moore EE, Ghasabyan A, Chin TL, Sauaia A, Banerjee A, Silliman CC: Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock 39(1):45-49, 2013.
67. Hunt H, Stanworth S, Curry N, Wooller T, Cooper C, Ukoumunne O, Zhelev Z, Hyde C: Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev 2:CD010438, 2015.
68. Schöchl H, Maegele M, Voelckel W: Fixed ratio versus goal-directed therapy in trauma. Curr Opin Anaesthesiol 29:234-244, 2016.
69. Levi M, Hunt BJA: A critical appraisal of point-of-care coagulation testing in critically ill patients. J Thromb Haemost 13(11):1960-1967, 2015.
70. Gonzalez E, Moore EE, Moore HB, Chapman MP, Chin TL, Ghasabyan A, Wohlauer MV, Barnett CC, Bensard DD, Biffl WL, et al.: Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg 263(6):1051-1059, 2016.
71. Rotational Thromboelastometry Applied Transfusion In Trauma. Available at: http://www.rotatetrial.com/. (Accessed: February 22, 2016).
72. Goodman MD, Makley AT, Hanseman DJ, Pritts TA, Robinson BR: All the bang without the bucks: Defining essential point-of-care testing for traumatic coagulopathy. J Trauma Acute Care Surg 79(1):117-124, 2015.
73. Ak K, Isbir CS, Tetik S, Atalan N, Tekeli A, Aljodi M, Civelek A, Arsan S: Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg 24(4):404-410, 2009.
74. Sun W, Jeleniowksi K, Zhao X, Shen P, Li D, Hammond JA: Thromboelas-tography (TEG)-based algorithm reduces blood product utilization in patients undergoing VAD implant. J Card Surg 29(2):238-243, 2014.
75. Wikkelsoe AJ, Afshari A, Wetterslev J, Brok J, Moeller AM: Monitoring patients at risk of massive transfusion with thrombelastography or thromboe-lastometry: a systematic review. Acta Anaesthesiol Scand 55(10):1174-1189, 2011.
76. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW Jr, Starzl TE, Winter PM: Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 64(9):888-896, 1985.
77. Novaković Anucin S, Kosanovic D, Grip S, Canak V, Cabarkapa V, Mitic G: Comparison of standard coagulation tests and rotational thromboelastography for hemostatic system monitoring during orthotopic liver transplantation-results from a pilot study. Med Pregl 68(9-10):301-307, 2015.
78. de Lange NM, Lance MD, de Groot R, Beckers EA, Henskens YM, Scheepers HC: Obstetric hemorrhage and coagulation: an update. Thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage. Obstet Gynecol Surv 67(7):426-435, 2012.
79. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al.: Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303(8):754-762, 2010.
80. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS: Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29(8):992-1000, 2008.
81. Swallow RA, Agarwala RA, Dawkins KD, Curzen NP: Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy? Platelets 17(6):385-392, 2006.
82. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, et al.: Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 105(10):4106-4114, 2005.
83. Blood safety. Available at: http://www.cdc.gov/bloodsafety/bbp/diseases-or-ganisms.html. Accessed July 16, 2016.
84. Butler C, Doree C, Estcourt LJ, Trivella M, Hopewell S, Brunskill SJ, Stan-worth S, Murphy MF: Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 3:CD009072, 2013.
85. Cid J, Escolar G, Lozano M: Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: Results of a meta-analysis of randomized controlled trials. Vox Sang 103(4):322-330, 2012.
86. Kleinman S: Pathogen inactivation: emerging indications. Curr Opin Hematol 22(6):547-553, 2015.
87. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, et al.: Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 104(5):1534-1541, 2004.
88. Lozano M, Knutson F, Tardivel R, Cid J, Maymó RM, Löf H, Roddie H, Pelly J, Docherty A, Sherman C, et al.: A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 153(3):393-401, 2011.
89. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Klüter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, et al.: Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 101(6):2426-2433, 2003.
90. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, et al.: Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 150(2):209-217, 2010.
91. Tobian AA, Fuller AK, Uglik K, Tisch DJ, Broge PD, Benjamin RJ, Ness PM, King KE: The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment. Transfusion 54(6):1523-1529, 2014.
92. Cohn CS, Stubbs J, Schwartz J, Francis R, Goss C, Cushing M, Shaz B, Mair D, Brantigan B, Heaton WA: A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion 54(8):1927-1934, 2014.
93. van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L: Functional characteristics of S-59 photochemically treated platelet concentrates from buffy coats. Vox Sang 79(4):206-214, 2000.
94. Mohr H, Gravemann U, Bayer A, Muller TH: Sterilization of platelets concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 49(9):1956-1963, 2009.
95. van der Meer PF: PAS or plasma for storage of platelets? A concise review. Transfusion Medicine 26:339-342, 2016.
96. Dudaryk R, Hess AS, Varon AJ, Hess JR: What is new in the blood bank for trauma resuscitation. Curr Opin Anaesthesiol 28(2):206-209, 2015.
97. Valeri CR, Ragno G, Khuri S: Freezing human platelets with 6 percent dimethyl sulfoxide with removal of the supernatant solution before freezing and storage at-80 degrees C without postthaw processing. Transfusion 45(12):1890-1898, 2005.
98. Valeri CR, Giorgio GR: Refrigerated platelets for the treatment of acute bleeding: a review of the literature and reexamination of current standards. Shock 43(3):298-299, 2015.
99. Capocelli KE, Dumont LJ: Novel platelet storage conditions: additive solutions, gas, and cold. Curr Opin Hematol 21(6):491-496, 2014.
100. Dumont LJ, Cancelas JA, Dumont DF, Siegel AH, Szczepiorkowski ZM, Rugg N, Pratt PG, Worsham DN, Hartman EL, Dunn SK, et al.: A randomized controlled trial evaluating recovery and survival of 6% dimethyl sulfoxide-frozen autologous plateletsinhealthy volunteers. Transfusion 53:128-137, 2013.
101. Slichter SJ, Jones M, Ransom J, Gettinger I, Jones MK, Christoffel T, Pellham E, Bailey SL, Corson J, Bolgiano D: Review of in vivo studies of dimethyl sulfoxide cryopreserved platelets. Transfus Med Rev 28:212-225, 2014.
102. Read MS, Reddick RL, Bode AP, Bellinger DA, Nichols TC, Taylor K, Smith SV, McMahon DK, Griggs TR, Brinkhous KM: Preservation of hemostatic and structural properties of rehydrated lyophilized platelets: potential for long-term storage of dried platelets for transfusion. Proc Natl Acad Sci USA 92:397-401, 1995.
103. Fischer TH, Bode AP, Parker BR, Russell KE, Bender DE, Ramer JK, Read MS: Primary and secondary hemostatic functionalities of rehydrated, lyophi-lized platelets. Transfusion 46:1943-1950, 2006.
104. Tang M, Wolkers WF, Crowe JH, Tablin F: Freeze-dried rehydrated human blood platelets regulate intracellular pH. Transfusion 46:1029-1037, 2006.
105. Arnold P, Djerassi I, Farber S, Freeman G, Klein E, Toch R: The preparation and clinical administration of lyophilized platelet material to children with acute leukemia and aplastic anemia. J Pediatr 49:517-522, 1956.
106. Stefanini M, Kistner SA: Platelets, platelet factors and platelet substitutes in the management of thrombocytopenic states. Bibl Haematol 7:378-381, 1958.
107. Inaba K, Barmparas G, Rhee P, Branco BC, Fitzpatrick M, Okoye OT, Deme-triades D: Dried platelet in a swine model of liver injury. Shock 41:429-434, 2014.
108. Davidow EB, Brainard B, Martin LG, Beal MW, Bode A, Ford MJ, Ramsey N, Fagella A, Jutkowitz A: Use of fresh platelet concentrate or lyophilized platelets in thrombocytopenic dogs with clinical signs of hemorrhage: a preliminary trial in 37 dogs. J Vet Emerg Crit Care (San Antonio) 22:116-125, 2012.
109. Hawksworth JS, Elster EA, Fryer D, Sheppard F, Morthole V, Krishnamurthy G, Tomori T, Brown TS, Tadaki DK: Evaluation of lyophilized platelets as an infusible hemostatic agent in experimental non-compressible hemorrhage in swine. J Thromb Haemost 7:1663-1671, 2009.
110. Bode AP, Lust RM, Read MS, Fischer TH: Correction of the bleeding time with lyophilized platelet infusions in dogs on cardiopulmonary bypass. Clin Appl Thromb Hemost 14:38-54, 2008.
111. Valeri CR, Macgregor H, Barnard MR, Summaria L, Micehlson AD, Ragno G: In vitro testing of fresh and lyophilized reconstituted human and baboon platelets. Transfusion 44:1505-1512, 2004.
112. Bode AP, Fischer TH: Lyophilized platelets: fifty years in the making. Artif Cells Blood Substit Immobil Biotechnol 5(1):125-133, 2007.
113. Fischer TH, Merricks E, Bellinger DA, Hayes PM, Smith RS, Raymer RA, Read MS, Nichols TC, Bode AP: Splenic clearance mechanisms of rehydrated, lyophilized platelets. Artif Cells Blood Substit Immobil Biotechnol 29:439-451, 2001.
114. Cap AP, Perkins JG: Lyophilized platelets: challenges and opportunities. J Trauma 70:S59-S60, 2011.
115. Transfusion Medicine Standards Program Unit. Standards for Blood Banks and Transfusion Services. 30th edition, Bethesda, MD: AABB Press; 2015.
116. US FDA. Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for FY2015. Available at: http://www.fda. gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM518148.pdf. Last accessed on 10/8/2016.
117. Rank A, Nieuwland R, Liebhardt S, Iberer M, Grutzner S, Toth B, Pihusch R: Apheresis platelet concentrates contain platelet-derived and endothelial cell-derived microparticles. Vox Sang 100(2):179-186, 2011.
118. Black A, Pienimaeki-Roemer A, Kenyon O, Orso E, Schmitz G: Platelet-derived extracellular vesicles in plateletpheresis concentrates as a quality control approach. Transfusion 55(9):2184-2196, 2015.
119. Maurer-Spurej E, Larsen R, Labrie A, Heaton A, Chipperfield K: Microparticle content ofplatelet concentrates ispredictedbydonor microparticles andisaltered by production methods and stress. Transfus Apher Sci 55(1):35-43, 2016.
120. Maurer E, Labrie A: Screening of donor platelet-rich plasma to predict platelet quality before production of apheresis platelet concentrates. J Clin Apheresis 30:72, 2015.
121. Blajchman MA: Substitutes for success. Nature Med 5:17-18, 1999.
122. Modery-Pawlowski CL, Tian LL, McCrae KR, Mitragotri S, Sen Gupta A: Approaches to synthetic platelet analogs. Biomaterials 34:526-541, 2013.
123. Solheim BG: Pathogen reduction of blood components. Transfus Apher Sci 39:75-82, 2008.
124. Stanworth SJ, Navarrete C, Estcourt L, Marsh J: Platelet refractoriness-practical approaches and ongoing dilemmas in patient management. Br J Haematol 171:297-305, 2015.
125. Blajchman MA: Immunomodulatory effects of allogeneic blood transfusions: clinical manifestations and mechanisms. Vox Sang 74:315-319, 1998.
126. Slichter SJ: Platelet refractoriness and alloimmunization. Leukemia 12:S51-S53, 1998.
127. Kaiser-Guignard J, Cenellini G, Lion N, Abonnenc M, Osselaer JC, Tissot JD: The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 28:235-241, 2014.
128. Lambert MP, Sullivan SK, Fuentes R, French DL, Poncz M: Challenges and promises for the development of donor independent platelet transfusions. Blood 121:3319-3324, 2013.
129. Chao FC, Kim BK, Houranieh AM, Liang FH, Konrad MW, Swisher SN, Tullis JL: Infusible platelet membrane microvesicles: a potential transfusion substitute for platelets. Transfusion 36:536-542, 1996.
130. Galán A-M, Bozzo J, Hernández M-R, Pino M, Reverter J-C, Mazzara R, Escolar G, Ordinas A: Infusible platelet membranes improve hemostasis in thrombocytopenic blood: experimental studies under flow conditions. Trans-fusion 40:1074-1080, 2004.
131. Nasiri S: Infusible platelet membrane as a platelet substitute for transfusion: an overview. Blood Transfusion 11:337-342, 2013.
132. Nasiri S, Mousavi HK: Infusible platelet membrane versus conventional platelet concentrate: benefits and disadvantages. Iranian J Blood Cancer 6:87-93, 2014.
133. Fitzpatrick GM, Cliff R, Tandon N: Thrombosomes: a platelet-derived hemo-static agent for control of noncompressible hemorrhage. Transfusion 53:100S-106S, 2013.
134. Rybak MEM, Renzulli LA: A liposome based platelet substitute, the plate-letsome, with hemostatic efficacy. Biomat Art Cells Immob Biotech 21:101-118, 1993.
135. Takeoka S, Teramura Y, Okamura Y, Tsuchida E, Handa M, Ikeda Y: Rolling properties of rGPIbalpha-conjugated phospholipid vesicles with different membrane flexibilities on vWf surface under flow conditions. Biochem Bio-phys Res Commun 296:765-770, 2002.
136. Nishiya T, Kainoh M, Murata M, Handa M, Ikeda Y: Reconstitutionof adhesive properties of human platelets in liposomes carrying both recombinant glyco-proteins Ia/IIa and Ib alpha under flow conditions: specific synergy of receptor-ligand interactions. Blood 100:136, 2002.
137. Nishiya T, Kainoh M, Murata M, Handa M, Ikeda Y: Platelet interactions with liposomes carrying recombinant platelet membrane glycoproteins or fibrino-gen: approach to platelet substitutes. Artif Cells Blood Substit Immobil Bio-technol 29:453-464, 2001.
138. Coller BS: Interaction of normal, thrombasthenic, and bernard-soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood 55:169-178, 1980.
139. Agam G, Livne AA: Erythrocytes with covalently bound fibrinogen as a cellular replacement for the treatment of thrombocytopenia. Eur J Clin Invest 22:105-112, 1992.
140. Yen RCK, Ho TWC, Blajchman MA: A new haemostatic agent: thrombo-spheres shorten the bleeding time in thrombocytopenic rabbits. Thrombosis Haemostasis 73:986, 1995.
141. Lee DH, Blajchman MA: Novel treatment modalities: new platelet prep-arations and substitutes. Br J Haematol 114:496-505, 2001.
142. Fuss C, Palmaz JC, Sprague EA: Fibrinogen: structure, function, and surface interactions. J Vasc Interv Radiol 12:677-682, 2001.
143. Mossesson MW: Fibrinogen and fibrin structure and functions. J Thromb Haemost 3:1894-1904, 2005.
144. Du X, Plow EF, Frelinger AL III, O'Toole TE, Loftus JC, Ginsberg MH: Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell 65:409-416, 1991.
145. Bennett JS: Structure and function of the platelet integrin aIIbb3. J Clin Invest 115:3363-3369, 2005.
146. Coller BS, Springer KT, Beer JH, Mohandas N, Scudder LE, Norton KJ, West SM: Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. J Clin Invest 89:546-555, 1992.
147. Takeoka S, Okamura Y, Teramura Y, Watanabe N, Suzuki H, Tsuchida E, Handa M, Ikeda Y: Function of fibrinogen g-chain dodecapeptide-conjugated latex beads under flow. Biochem Biophys Res Comm 312:773-779, 2003.
148. Bertram JP, Williams CA, Robinson R, Segal SS, Flynn NT, Lavik EB: Intravenous hemostat: nanotechnology to halt bleeding. Sci Transl Med 1:11-22, 2009.
149. Lashoff-Sullivan MM, Shoffstall AE, Atkins KT, Keane N, Bir C, VandeVord P, Lavik EB: Intravenously administered nanoparticles increase survival follow-ing blast trauma. Proc Natl Acad Sci USA 111:10293-10298, 2014.
150. Hoffman M, Monroe DM III: A cell-based model of hemostasis. Thromb Haemost 85:958-965, 2001.
151. Nishiya T, Kainoh M, Murata M, Handa M, Ikeda Y: Reconstitutionofadhesive properties of human platelets in liposomes carrying both recombinant glyco-proteins Ia/IIa and Ib alpha under flow conditions: specific synergy of receptor-ligand interactions. Blood 100:136-142, 2002.
152. Ravikumar M, Modery CL, Wong TL, Sen Gupta A: Peptide-decorated lip-osomes promote arrest and aggregation of activated platelets under flow on vascular injury relevant protein surfaces in vitro. Biomacromolecules 13:1495-1502, 2012.
153. Modery-Pawlowski CL, Tian LL, Ravikumar M, Wong TL, Sen Gupta A: In vitro and in vivo hemostatic capabilities of a functionally integrated platelet-mimetic liposomal nanoconstruct. Biomaterials 34:3031-3041, 2013.
154. Anselmo AC, Modery-Pawlowski C, Menegatti S, Kumar S, Vogus DR, Tian LL, Chen M, Squires TM, Sen Gupta A, Mitragotri S: Platelet-like nano-particles: mimicking shape, flexibility, and surface biology of platelets to target vascular injuries. ACS Nano 8:11243-11253, 2014.
155. Sen Gupta A, Ravikumar M. US Patent: Synthetic Platelets. US 9107845. 2015.
156. Avanzi MP, Mitchell WB: Ex vivo production of platelets from stem cells. Br J Haematol 165:237-247, 2014.
157. Nakamura S, Takayama N, Hirata S, Seo H, Endo H, Ochi K, Fujita K, Koike T, Harimoto K, Dohda T, et al.: Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells. Cell Stem Cell 14:535-548, 2014.
158. Thon JN, Mazutis L, Wu S, Sylman JL, Ehrlicher A, Machlus KR, Feng Q, Lu S, Lanza R, Neeves KB, et al.: Platelet bioreactor-on-a-chip. Blood 124:1857-1867, 2014.